Opinion|Videos|June 3, 2025
Using Ultrasensitive PSA Assays in Routine Practice
Author(s)Neal Shore, MD, FACS
Explore the potential of ultra-low PSA testing in managing metastatic hormone-sensitive prostate cancer, balancing accessibility and cost considerations.
Advertisement
Episodes in this series
Practical Considerations for Ultrasensitive PSA Testing
Key Themes:
- Feasibility of implementing ultrasensitive PSA assays in community practice
- Logistical challenges including cost and standardization
- Clinical interpretation considerations
Expert Insights:
- Dr Shore addressed the practicality of using ultrasensitive PSA assays in routine clinical practice.
The discussion covered pros and cons, cost implications, assay standardization challenges, and the nuances of clinical interpretation.
Advertisement
Related to this article
Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Moderators and participants reviewed ARANOTE, ARACOG, and ARASEC data and how they inform individualized treatment for mCSPC.
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
Engy Habashy, MD, on the role of androgens in GSM management
4
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
5